Email me at Mike Emery. All financial contributions are cheerfully accepted. If you want to keep it private, use my PGP Key
Lots of money rides on pharmaceutical research. New drugs have to get formal acceptance by government agencies in different countries. Checking for dangerous side effects is not easy so testing takes years. The final decision is basically a gamble as far as the researchers are concerned. Helping these things along can get too involved as Doctor Blumsohn discovered. Ditto for the Genetic Modification boondoggle.
Aubrey Blumsohn and Proctor & Gamble
QUOTE
Blumsohn was employed at Sheffield University as a senior lecturer and honorary consultant in metabolic bone disease. He was engaged on a joint research project with Procter & Gamble Pharmaceutical, which funded the work and had a commercial interest in the outcome. He was asked to publish in his own name academic papers prepared by a writer working on behalf of Procter & Gamble Pharmaceutical about the effects on patients of the anti-osteoporosis drug Actonel. When Dr Blumsohn asked to see the raw data underlying the draft papers, initially the request was refused. Eventually he had limited access to the data he had requested and found that some of the data underlying the findings he was asked to endorse was omitted from the statistical analysis. When Dr Blumsohn raised a concern about his name being put to such a paper he was reminded of the substantial income that Sheffield University received from Procter & Gamble Pharmaceutical. Later he was suspended. He was offered a severance payment in return for signing a gagging clause.
UNQUOTE
He went away. Will he need to work again? Pass. Will he be able to work again? Pass.
Errors & omissions,
broken links, cock ups, over-emphasis, malice [ real or imaginary ] or whatever;
if you find any I am open to comment.
Email me at Mike
Emery.
All financial contributions are cheerfully accepted. If you want to keep it
private, use my PGP Key
Updated on Wednesday, 18 July 2012 18:38:42